| 1 | patients faster and more | | | | | | | 3 | 0.87% |
| 2 | new treatments to patients | | | | | | | 3 | 0.87% |
| 3 | treatments to patients faster | | | | | | | 3 | 0.87% |
| 4 | to patients faster and | | | | | | | 3 | 0.87% |
| 5 | the pharma company of | | | | | | | 2 | 0.58% |
| 6 | drug development is done | | | | | | | 2 | 0.58% |
| 7 | way drug development is | | | | | | | 2 | 0.58% |
| 8 | the way drug development | | | | | | | 2 | 0.58% |
| 9 | ainative pharma company changing | | | | | | | 2 | 0.58% |
| 10 | techdriven ainative pharma company | | | | | | | 2 | 0.58% |
| 11 | a techdriven ainative pharma | | | | | | | 2 | 0.58% |
| 12 | are a techdriven ainative | | | | | | | 2 | 0.58% |
| 13 | we are a techdriven | | | | | | | 2 | 0.58% |
| 14 | efficiently we are a | | | | | | | 2 | 0.58% |
| 15 | pharma company of the | | | | | | | 2 | 0.58% |
| 16 | faster and more efficiently | | | | | | | 2 | 0.58% |
| 17 | bring new treatments to | | | | | | | 2 | 0.58% |
| 18 | to bring new treatments | | | | | | | 2 | 0.58% |
| 19 | is to bring new | | | | | | | 2 | 0.58% |
| 20 | mission is to bring | | | | | | | 2 | 0.58% |
| 21 | our mission is to | | | | | | | 2 | 0.58% |
| 22 | company of the future | | | | | | | 2 | 0.58% |
| 23 | products that actually make | | | | | | | 1 | 0.29% |
| 24 | make it into the | | | | | | | 1 | 0.29% |
| 25 | actually make it into | | | | | | | 1 | 0.29% |
| 26 | that actually make it | | | | | | | 1 | 0.29% |
| 27 | known potential treatments and | | | | | | | 1 | 0.29% |
| 28 | few products that actually | | | | | | | 1 | 0.29% |
| 29 | comparatively few products that | | | | | | | 1 | 0.29% |
| 30 | potential treatments and the | | | | | | | 1 | 0.29% |
| 31 | into the hands of | | | | | | | 1 | 0.29% |
| 32 | of known potential treatments | | | | | | | 1 | 0.29% |
| 33 | backlog of known potential | | | | | | | 1 | 0.29% |
| 34 | it into the hands | | | | | | | 1 | 0.29% |
| 35 | drug development ecosystem can’t | | | | | | | 1 | 0.29% |
| 36 | patients the existing drug | | | | | | | 1 | 0.29% |
| 37 | the existing drug development | | | | | | | 1 | 0.29% |
| 38 | existing drug development ecosystem | | | | | | | 1 | 0.29% |
| 39 | between the backlog of | | | | | | | 1 | 0.29% |
| 40 | development ecosystem can’t keep | | | | | | | 1 | 0.29% |